The ISoP CommSIG for Improving Medicinal Product Risk Communication: A New Special Interest Group of the International Society of Pharmacovigilance

dc.contributor.authorBahri, P.
dc.contributor.authorDodoo, A.N.
dc.contributor.authorEdwards, B.D.
dc.contributor.authorEdwards, I.R.
dc.contributor.authorFermont, I.
dc.contributor.authorHagemann, U.
dc.contributor.authorHartigan-Go, K.
dc.contributor.authorHugman, B.
dc.contributor.authorMol, P.G.
dc.date.accessioned2018-09-14T11:23:14Z
dc.date.available2018-09-14T11:23:14Z
dc.date.issued2015-07
dc.description.abstractCommunicating to patients and healthcare providers about the risks of harm with medicines and how to use medicines safely is vital to pharmacovigilance for fulfilling its objectives—there is no or little risk avoidance/mitigation or patient safety without risk communication. Communication about risk characteristics and factors should also enable patients and healthcare providers to make informed therapeutic choices. This requires discussing risks of medicines in the context of their benefits as well as the risks of deciding against medication. Usually medicines are meant to benefit the individuals taking them. In the area of infectious diseases, however, vaccines are aimed at protecting the vaccinee and also, through repressing or eradicating the disease, protecting vulnerable individuals who cannot be vaccinated.en_US
dc.identifier.otherVolume 38, Issue 7, pp 621–627
dc.identifier.otherdoi: 10.1007/s40264-015-0301-0.
dc.identifier.urihttp://ugspace.ug.edu.gh/handle/123456789/24180
dc.language.isoenen_US
dc.publisherDrug Safetyen_US
dc.subjectPharmacovigilanceen_US
dc.subjectISoP CommSIGen_US
dc.subjectMedicinal Producten_US
dc.subjectInternational Societyen_US
dc.titleThe ISoP CommSIG for Improving Medicinal Product Risk Communication: A New Special Interest Group of the International Society of Pharmacovigilanceen_US
dc.typeOtheren_US

Files

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.6 KB
Format:
Item-specific license agreed upon to submission
Description: